Related Experiment Videos
The effect of valproic acid on plasma carnitine levels
Insights
Valproic acid treatment in children significantly lowers free carnitine levels, especially with polytherapy. This indicates a potential decrease in the carnitine pool for patients on valproic acid medications.
Area of Science:
- Biochemistry
- Pediatric Neurology
- Pharmacology
Background:
- Carnitine is essential for fatty acid metabolism.
- Valproic acid is a widely used antiepileptic drug.
- Alterations in carnitine levels can impact metabolic health.
Purpose of the Study:
- To investigate the impact of valproic acid monotherapy and polytherapy on plasma carnitine levels in children.
- To compare carnitine levels in children treated with valproic acid versus other antiepileptic drugs or no antiepileptics.
Main Methods:
- Measurement of plasma total, free, and acyl carnitine levels.
- Comparison of four groups: valproic acid monotherapy, valproic acid polytherapy, other antiepileptic drugs, and normal controls.
- Statistical analysis to determine significant differences between groups.
Main Results:
- Significantly lower free carnitine levels were observed in both valproic acid monotherapy and polytherapy groups compared to normal controls and those on other antiepileptics.
- Polytherapy with valproic acid resulted in lower free carnitine levels than monotherapy.
- Elevated acyl to free carnitine ratios were found in valproic acid-treated groups.
Conclusions:
- Valproic acid therapy, particularly polytherapy, is associated with a significant decrease in the plasma carnitine pool in children.
- Monitoring carnitine levels may be warranted for children undergoing valproic acid treatment.
- Other antiepileptic drugs, when used alone, did not appear to affect carnitine levels.
Abstract:
Plasma total, free, and acyl carnitine levels were determined in four groups of children: (1) those treated with valproic acid as monotherapy (n = 43), (2) those treated with valproic acid plus other antiepileptics as polytherapy (n = 91), (3) those treated with other antiepileptic drugs alone (n = 43), and (4) normal patients (n = 89). The mean free carnitine level was significantly lower in both the valproic acid monotherapy (29.9 mumol/L) and polytherapy (21.4 mumol/L) groups compared with normal subjects (36.8 mumol/L); it was also significantly lower than that in patients treated with other antiepileptic drugs (36.7 mumol/L). Comparison of valproic acid polytherapy and monotherapy yielded significantly lower free carnitine levels in the polytherapy group. The ratios of acyl to free carnitine for monotherapy (0.41) and polytherapy (0.45) were significantly higher than that in the normal group (0.25). This study indicates that a general decrease in the carnitine pool should be anticipated in patients taking valproic acid polytherapy and, to a lesser degree, monotherapy. Carnitine levels in the group taking other drugs did not differ from normal.